- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 810915, 14 pages
Analytical Variables Affecting Analysis of F2-Isoprostanes and F4-Neuroprostanes in Human Cerebrospinal Fluid by Gas Chromatography/Mass Spectrometry
Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan 333, Taiwan
Received 19 February 2013; Accepted 13 May 2013
Academic Editor: Shih-Bin Su
Copyright © 2013 Hsiu-Chuan Yen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. Halliwell and M. C. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, New York, NY, USA, 2007.
- L. J. Roberts II and J. D. Morrow, “The generation and actions of isoprostanes,” Biochimica et Biophysica Acta, vol. 1345, no. 2, pp. 121–135, 1997.
- D. M. Stafforini, J. R. Sheller, T. S. Blackwell et al., “Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases,” Journal of Biological Chemistry, vol. 281, no. 8, pp. 4616–4623, 2006.
- U. Jahn, J.-M. Galano, and T. Durand, “Beyond prostaglandins—chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids,” Angewandte Chemie, vol. 47, no. 32, pp. 5894–5955, 2008.
- G. L. Milne, H. Yin, K. D. Hardy, S. S. Davies, and L. J. Roberts, “Isoprostane generation and function,” Chemical Reviews, vol. 111, no. 10, pp. 5973–5996, 2011.
- G. L. Milne, H. Yin, and J. D. Morrow, “Human biochemistry of the isoprostane pathway,” Journal of Biological Chemistry, vol. 283, no. 23, pp. 15533–15537, 2008.
- L. J. Roberts II and J. D. Morrow, “Measurement of F2-isoprostanes as an index of oxidative stress in vivo,” Free Radical Biology and Medicine, vol. 28, no. 4, pp. 505–513, 2000.
- L. J. Roberts II, T. J. Montine, W. R. Markesbery et al., “Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid,” Journal of Biological Chemistry, vol. 273, no. 22, pp. 13605–13612, 1998.
- H. Yin, E. S. Musiek, L. Gao, N. A. Porter, and J. D. Morrow, “Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo,” Journal of Biological Chemistry, vol. 280, no. 28, pp. 26600–26611, 2005.
- K. S. Montine, J. F. Quinn, J. Zhang et al., “Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases,” Chemistry and Physics of Lipids, vol. 128, no. 1-2, pp. 117–124, 2004.
- G. L. Milne, S. C. Sanchez, E. S. Musiek, and J. D. Morrow, “Quantification of F2-isoprostanes as a biomarker of oxidative stress,” Nature Protocols, vol. 2, no. 1, pp. 221–226, 2007.
- W. Liu, J. D. Morrow, and H. Yin, “Quantification of F2-isoprostanes as a reliable index of oxidative stress in vivo using gas chromatography-mass spectrometry (GC-MS) method,” Free Radical Biology and Medicine, vol. 47, no. 8, pp. 1101–1107, 2009.
- Y. P. Hsieh, C. L. Lin, A. L. Shiue et al., “Correlation of F4-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans,” Free Radical Biology and Medicine, vol. 47, no. 6, pp. 814–824, 2009.
- G. L. Milne, H. Yin, J. D. Brooks, S. Sanchez, L. Jackson Roberts II, and J. D. Morrow, “Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress,” Methods in Enzymology, vol. 433, pp. 113–126, 2007.
- K. O. Arneson and L. J. Roberts II, “Measurement of products of docosahexaenoic acid peroxidation, neuroprostanes, and neurofurans,” Methods in Enzymology, vol. 433, pp. 127–143, 2007.
- H. C. Yen, “Detection of F2-isoprostanes and F4-neuroprostanes in clinical studies,” Journal of Biomedical Laboratory Science, vol. 22, no. 1, pp. 1–10, 2010.
- C. L. Lin, Y. T. Hsu, T. K. Lin et al., “Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans,” Free Radical Biology and Medicine, vol. 40, no. 8, pp. 1466–1473, 2006.
- T. B. Corcoran, E. Mas, A. E. Barden et al., “Are isofurans and neuroprostanes increased after subarachnoid hemorrhage and traumatic brain injury?” Antioxidants and Redox Signaling, vol. 15, no. 10, pp. 2663–2667, 2011.
- T. J. Montine, J. Quinn, J. Kaye, and J. D. Morrow, “F2-isoprostanes as biomarkers of late-onset Alzheimer's disease,” Journal of Molecular Neuroscience, vol. 33, no. 1, pp. 114–119, 2007.
- T. J. Montine, M. F. Beal, D. Robertson et al., “Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease,” Neurology, vol. 52, no. 5, pp. 1104–1105, 1999.
- M. J. De Leon, L. Mosconi, J. Li et al., “Longitudinal CSF isoprostane and MRI atrophy in the progression to AD,” Journal of Neurology, vol. 254, no. 12, pp. 1666–1675, 2007.
- G. L. Milne, B. Gao, E. S. Terry, W. E. Zackert, and S. C. Sanchez, “Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry,” Free Radical Biology & Medicine, vol. 59, pp. 36–44, 2013.
- H. C. Yen, H. S. Cheng, Y. T. Hsu, H. J. Ho, C. Y. Nien, and Y. S. Lee, “Effects of age and health status on levels of urinary 15-F2t-isoprostane,” Journal of Biomedical Laboratory Science, vol. 13, pp. 24–28, 2001.
- E. Mas, A. Barden, T. Durand, J.-M. Galano, K. D. Croft, and T. A. Mori, “Measurement of urinary F2-isoprostanes by gas chromatography-mass spectrometry is confounded by interfering substances,” Free Radical Research, vol. 44, no. 2, pp. 191–198, 2010.
- S. Basu, “F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications,” Antioxidants and Redox Signaling, vol. 10, no. 8, pp. 1405–1434, 2008.
- T. J. Montine, M. F. Beal, M. E. Cudkowicz et al., “Increased CSF F2-isoprostane concentration in probable AD,” Neurology, vol. 52, no. 3, pp. 562–565, 1999.
- T. W. Chen, C. L. Lin, and H. C. Yen, “Elevation of F2-isoprostanes and F4-neuroprostanes levels in cerebrospinal fluid of patients with traumatic brain injury,” Free Radical Biology & Medicine, vol. 47, Abstract S108, 2009.
- D. Milatovic, M. VanRollins, K. Li, K. S. Montine, and T. J. Montine, “Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by α- or γ-tocopherol,” Journal of Chromatography B, vol. 827, no. 1, pp. 88–93, 2005.
- G. L. Milne, J. D. Morrow, and M. J. Picklo Sr., “Elevated oxidation of docosahexaenoic acid, 22:6 (n − 3), in brain regions of rats undergoing ethanol withdrawal,” Neuroscience Letters, vol. 405, no. 3, pp. 172–174, 2006.
- Y. Zhang, D. Milatovic, M. Aschner, P. J. Feustel, and H. K. Kimelberg, “Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity,” Experimental Neurology, vol. 204, no. 2, pp. 819–827, 2007.
- J. Nourooz-Zadeh, E. H. C. Liu, B. Yhlen, E. E. Änggård, and B. Halliwell, “F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease,” Journal of Neurochemistry, vol. 72, no. 2, pp. 734–740, 1999.